Gluten in Medicine Disclosure Act of 2019

Senate Bill 3021 - Gluten in Medicine Disclosure Act of 2019: Overview, Status, and Impact

Hozzl · 2022-10-28T01:45:59Z

Explore the details of Senate Bill 3021 Gluten in Medicine Disclosure Act of 2019 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/28/2022, 1:45 AM

Congressional Summary of S 3021

Gluten in Medicine Disclosure Act of 2019

This bill prohibits the sale of any drug intended for human use that contains an ingredient derived from a gluten-containing grain unless the drug's label (1) states that the drug contains such an ingredient, and (2) identifies the type of grain from which the ingredient is derived.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3021

Bill S 3021 is currently in the status of Bill Introduced since December 11, 2019. Bill S 3021 was introduced during Congress 116 and was introduced to the Senate on December 11, 2019. Bill S 3021's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of December 11, 2019

Bipartisan Support of Bill S 3021

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3021

Primary Policy Focus

Health

Potential Impact Areas

- Consumer affairs

- Drug safety, medical device, and laboratory regulation

- Grain

- Nutrition and diet

- Prescription drugs

Alternate Title(s) of Bill S 3021

Gluten in Medicine Disclosure Act of 2019

A bill to amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug that is intended for human use and contains an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient, and for other purposes.